General Information of Drug Off-Target (DOT) (ID: OTBCSG50)

DOT Name Charged multivesicular body protein 4a (CHMP4A)
Synonyms Chromatin-modifying protein 4a; CHMP4a; SNF7 homolog associated with Alix-2; SNF7-1; hSnf-1; Vacuolar protein sorting-associated protein 32-1; Vps32-1; hVps32-1
Gene Name CHMP4A
Related Disease
Fragile X syndrome ( )
Myopia ( )
UniProt ID
CHM4A_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
3C3O; 5MK1
Pfam ID
PF03357
Sequence
MSGLGRLFGKGKKEKGPTPEEAIQKLKETEKILIKKQEFLEQKIQQELQTAKKYGTKNKR
AALQALRRKKRFEQQLAQTDGTLSTLEFQREAIENATTNAEVLRTMELAAQSMKKAYQDM
DIDKVDELMTDITEQQEVAQQISDAISRPMGFGDDVDEDELLEELEELEQEELAQELLNV
GDKEEEPSVKLPSVPSTHLPAGPAPKVDEDEEALKQLAEWVS
Function
Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. When overexpressed, membrane-assembled circular arrays of CHMP4A filaments can promote or stabilize negative curvature and outward budding. Via its interaction with PDCD6IP involved in HIV-1 p6- and p9-dependent virus release. CHMP4A/B/C are required for the exosomal release of SDCBP, CD63 and syndecan.
Tissue Specificity Widely expressed. Expressed at higher level in heart, kidney, liver and skeletal muscle. Also expressed in brain, placenta, lung and pancreas.
KEGG Pathway
Viral life cycle - HIV-1 (hsa03250 )
Endocytosis (hsa04144 )
Necroptosis (hsa04217 )
Reactome Pathway
Macroautophagy (R-HSA-1632852 )
Pyroptosis (R-HSA-5620971 )
Endosomal Sorting Complex Required For Transport (ESCRT) (R-HSA-917729 )
HCMV Late Events (R-HSA-9610379 )
Late endosomal microautophagy (R-HSA-9615710 )
Sealing of the nuclear envelope (NE) by ESCRT-III (R-HSA-9668328 )
Translation of Replicase and Assembly of the Replication Transcription Complex (R-HSA-9679504 )
Translation of Replicase and Assembly of the Replication Transcription Complex (R-HSA-9694676 )
Budding and maturation of HIV virion (R-HSA-162588 )

Molecular Interaction Atlas (MIA) of This DOT

2 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Fragile X syndrome DISE8W3A Strong Altered Expression [1]
Myopia DISK5S60 Strong Biomarker [2]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
5 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the expression of Charged multivesicular body protein 4a (CHMP4A). [3]
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Charged multivesicular body protein 4a (CHMP4A). [4]
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of Charged multivesicular body protein 4a (CHMP4A). [5]
Piroxicam DMTK234 Approved Piroxicam increases the expression of Charged multivesicular body protein 4a (CHMP4A). [6]
Bisphenol A DM2ZLD7 Investigative Bisphenol A increases the expression of Charged multivesicular body protein 4a (CHMP4A). [7]
------------------------------------------------------------------------------------

References

1 ESCRT-III Membrane Trafficking Misregulation Contributes To Fragile X Syndrome Synaptic Defects.Sci Rep. 2017 Aug 17;7(1):8683. doi: 10.1038/s41598-017-09103-6.
2 Myopic (HD-PTP, PTPN23) selectively regulates synaptic neuropeptide release.Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1617-1622. doi: 10.1073/pnas.1716801115. Epub 2018 Jan 29.
3 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
4 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
5 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
6 Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
7 Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.